Literature DB >> 16439562

Identification of spliced gammaherpesvirus 68 LANA and v-cyclin transcripts and analysis of their expression in vivo during latent infection.

Robert D Allen1, Shelley Dickerson, Samuel H Speck.   

Abstract

Regulation of orf73 (LANA) gene expression is critical to the establishment and maintenance of latency following infection by members of the gamma-2 herpesvirus (rhadinovirus) family. Previous studies of murine gammaherpesvirus 68 (gammaHV68) have demonstrated that loss of LANA function results in a complete failure to establish virus latency in the spleens of laboratory mice. Here we report the characterization of alternatively spliced LANA and v-cyclin (orf72) transcripts encoded by gammaHV68. Similar to other rhadinoviruses, alternative splicing, coupled with alternative 3' processing, of a ca. 16-kb transcriptional unit can lead to expression of either LANA or v-cyclin during gammaHV68 infection. Spliced LANA and v-cyclin transcripts were initially identified from an analysis of the gammaHV68 latently infected B-cell lymphoma cell line S11E, but were also detected during lytic infection of NIH 3T12 fibroblasts. 5' Random amplification of cDNA ends (RACE) analyses identified two distinct promoters, p1 and p2, that drive expression of spliced LANA transcripts. Analysis of p1 and p2, using transiently transfected reporter constructs, mapped the minimal sequences required for promoter activity and demonstrated that both promoters are active in the absence of any viral antigens. Analysis of spliced LANA and v-cyclin transcripts in spleens recovered from latently infected mice at days 16 and 42 postinfection revealed that spliced v-cyclin transcripts can only be detected sporadically, suggesting that these may be associated with cells reactivating from latency. In contrast, spliced LANA transcripts were detected in ca. 1 in 4,000 splenocytes harvested at day 16 postinfection. Notably, based on the frequency of viral genome-positive splenocytes at day 16 postinfection (ca. 1 in 200), only 5 to 10% of viral genome-positive splenocytes express LANA. The failure of the majority of infected splenocytes at day 16 postinfection to express LANA may contribute to the contraction in the frequency of latently infected splenocytes as chronic infection is established, due to failure to maintain the viral episome in proliferating B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439562      PMCID: PMC1367133          DOI: 10.1128/JVI.80.4.2055-2062.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.

Authors:  Jianhong Hu; Alexander C Garber; Rolf Renne
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Transcriptome profile of murine gammaherpesvirus-68 lytic infection.

Authors:  Bahram Ebrahimi; Bernadette M Dutia; Kim L Roberts; Jose J Garcia-Ramirez; Paul Dickinson; James P Stewart; Peter Ghazal; Douglas J Roy; Anthony A Nash
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

3.  Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes.

Authors:  Linda F van Dyk; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin.

Authors:  S K Dhar; K Yoshida; Y Machida; P Khaira; B Chaudhuri; J A Wohlschlegel; M Leffak; J Yates; A Dutta
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

5.  Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus.

Authors:  B Chaudhuri; H Xu; I Todorov; A Dutta; J L Yates
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

6.  The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency.

Authors:  Nathaniel J Moorman; David O Willer; Samuel H Speck
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Transcription program of murine gammaherpesvirus 68.

Authors:  DeeAnn Martinez-Guzman; Tammy Rickabaugh; Ting-Ting Wu; Helen Brown; Steven Cole; Moon Jung Song; Leming Tong; Ren Sun
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Long-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo.

Authors:  David O Willer; Samuel H Speck
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Gamma-herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells.

Authors:  Emilio Flaño; In-Jeong Kim; David L Woodland; Marcia A Blackman
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

10.  ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency.

Authors:  Polly Fowler; Sofia Marques; J Pedro Simas; Stacey Efstathiou
Journal:  J Gen Virol       Date:  2003-12       Impact factor: 3.891

View more
  22 in total

1.  Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection.

Authors:  Benson Yee Hin Cheng; Jizu Zhi; Alexis Santana; Sohail Khan; Eduardo Salinas; J Craig Forrest; Yueting Zheng; Shirin Jaggi; Janet Leatherwood; Laurie T Krug
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Evidence for CDK-dependent and CDK-independent functions of the murine gammaherpesvirus 68 v-cyclin.

Authors:  Jason W Upton; Samuel H Speck
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

3.  The ORF49 protein of murine gammaherpesvirus 68 cooperates with RTA in regulating virus replication.

Authors:  Sangmi Lee; Hye-Jeong Cho; Jung-Jin Park; Yong-Sun Kim; Seungmin Hwang; Ren Sun; Moon Jung Song
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters.

Authors:  Matthias Ottinger; Daniel Pliquet; Thomas Christalla; Ronald Frank; James P Stewart; Thomas F Schulz
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

5.  The de novo methyltransferases DNMT3a and DNMT3b target the murine gammaherpesvirus immediate-early gene 50 promoter during establishment of latency.

Authors:  Kathleen S Gray; J Craig Forrest; Samuel H Speck
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

6.  Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes but not long-term carriage of viral genome.

Authors:  Clinton R Paden; J Craig Forrest; Nathaniel J Moorman; Samuel H Speck
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

7.  Use of a virus-encoded enzymatic marker reveals that a stable fraction of memory B cells expresses latency-associated nuclear antigen throughout chronic gammaherpesvirus infection.

Authors:  Michael S Nealy; Carrie B Coleman; Haiyan Li; Scott A Tibbetts
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

8.  Stress-inducible alternative translation initiation of human cytomegalovirus latency protein pUL138.

Authors:  Lora Grainger; Louis Cicchini; Michael Rak; Alex Petrucelli; Kerry D Fitzgerald; Bert L Semler; Felicia Goodrum
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

9.  Identification of an Rta responsive promoter involved in driving gammaHV68 v-cyclin expression during virus replication.

Authors:  Robert D Allen; Mark N DeZalia; Samuel H Speck
Journal:  Virology       Date:  2007-05-02       Impact factor: 3.616

10.  Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus.

Authors:  Alex Petrucelli; Michael Rak; Lora Grainger; Felicia Goodrum
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.